GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Cash Ratio

BioAdaptives (BioAdaptives) Cash Ratio : 0.03 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. BioAdaptives's Cash Ratio for the quarter that ended in Dec. 2023 was 0.03.

BioAdaptives has a Cash Ratio of 0.03. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for BioAdaptives's Cash Ratio or its related term are showing as below:

BDPT' s Cash Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.03   Max: 0.96
Current: 0.03

During the past 9 years, BioAdaptives's highest Cash Ratio was 0.96. The lowest was 0.02. And the median was 0.03.

BDPT's Cash Ratio is ranked worse than
91.03% of 1840 companies
in the Consumer Packaged Goods industry
Industry Median: 0.39 vs BDPT: 0.03

BioAdaptives Cash Ratio Historical Data

The historical data trend for BioAdaptives's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Cash Ratio Chart

BioAdaptives Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 0.02 - 0.07 0.02 0.03

BioAdaptives Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - 0.02 0.10 0.03

Competitive Comparison of BioAdaptives's Cash Ratio

For the Packaged Foods subindustry, BioAdaptives's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAdaptives's Cash Ratio Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Cash Ratio distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Cash Ratio falls into.



BioAdaptives Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

BioAdaptives's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.061/1.751
=0.03

BioAdaptives's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.061/1.751
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioAdaptives  (OTCPK:BDPT) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


BioAdaptives Cash Ratio Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAdaptives (BioAdaptives) Business Description

Traded in Other Exchanges
N/A
Address
2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.
Executives
Richard Chiang other: Previous Officer and Director 460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling director 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc. 10 percent owner 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling director, officer: Pres, CEO, Secretary, CFO 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128

BioAdaptives (BioAdaptives) Headlines

From GuruFocus

BioAdaptives Sponsors COVID-19 Long Hauler Survey

By GuruFocusNews GuruFocusNews 06-12-2022